Cost-effectivity analysis of photodynamic therapy with Foscan® (Foscan®-PDT) compared with a palliative chemotherapy in patients with advanced head and neck tumors in Germany

Background: The purpose of this manuscript is to give a cost-effectiveness analysis of the photodynamic therapy by means of Foscan((R)) (Foscan((R))-PDT) in Germany. The basis for this paper is provided by a study performed in Great Britain which analyses the costs of Foscan((R))-PDT compared to the costs of palliative chemotherapy and to the option of no treatment in patients with advanced head and neck cancer. Method: In order to calculate the cost-effectiveness, an already published model developed on the base of English data was fed with German cost-data. For consideration of the different characteristics of cost-parameters as well as to minimize the over- or underestimation of the costs, sensitivity analyses were performed. Results: The Foscan((R))-PDT revealed the highest health-related effectiveness compared to all other above-mentioned options - 129 additional days of life in comparison to no treatment or 48 days in comparison to four cycles of palliative chemotherapy. The costs per therapy of Foscan((R))-PDT (8761 euro) were lower than those of four cycles of palliative chemotherapy (11600 euro). Conclusion: Foscan((R))-PDT is a cost-effective treatment option for patients suffering from advanced head and neck cancer. For patients who up to now had only very limited treatment possibilities at their disposition, Foscan((R))-PDT offers a chance for reduction of the tumor, remission, and a prolonged expectancy of life.